Εμφάνιση απλής εγγραφής

dc.creatorGiustozzi M., Acciarresi M., Agnelli G., Caso V., Bandini F., Tsivgoulis G., Yaghi S., Furie K.L., Tadi P., Becattini C., Zedde M., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., D'Amore C., Giulia Mosconi M., Anna Cimini L., Bovi P., Carletti M., Rigatelli A., Cappellari M., Putaala J., Tomppo L., Tatlisumak T., Marcheselli S., Pezzini A., Poli L., Padovani A., Vannucchi V., Sohn S.-I., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Ntaios G., Athanasakis G., Makaritsis K., Karagkiozi E., Vadikolias K., Liantinioti C., Theodorou A., Halvatsiotis P., Mumoli N., Galati F., Sacco S., Tiseo C., Corea F., Ageno W., Bellesini M., Silvestrelli G., Ciccone A., Lanari A., Scoditti U., Denti L., Mancuso M., Ferrari E., Ulivi L., Orlandi G., Giannini N., Tassinari T., Luisa De Lodovici M., Rueckert C., Baldi A., Toni D., Letteri F., Giuntini M., Maria Lotti E., Flomin Y., Pieroni A., Kargiotis O., Karapanayiotides T., Monaco S., Maimone Baronello M., Csiba L., Szabó L., Chiti A., Giorli E., Del Sette M., Imberti D., Zabzuni D., Doronin B., Volodina V., Michel P., Vanacker P., Barlinn K., Barlinn J., Deleu D., Gourbali V., Paciaroni M., Masotti L.en
dc.date.accessioned2023-01-31T07:42:30Z
dc.date.available2023-01-31T07:42:30Z
dc.date.issued2020
dc.identifier10.1161/STROKEAHA.120.030143
dc.identifier.issn00392499
dc.identifier.urihttp://hdl.handle.net/11615/72420
dc.description.abstractBackground and Purpose: The optimal timing for starting oral anticoagulant after an ischemic stroke related to atrial fibrillation remains a challenge, mainly in patients treated with systemic thrombolysis or mechanical thrombectomy. We aimed at assessing the incidence of early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with thrombolytic therapy and/or thrombectomy, who then received oral anticoagulants for secondary prevention. Methods: We combined the dataset of the RAF and the RAF-NOACs (Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin K Oral Anticoagulants) studies, which were prospective observational studies carried out from January 2012 to March 2014 and April 2014 to June 2016, respectively. We included consecutive patients with acute ischemic stroke and atrial fibrillation treated with either Vitamin K antagonists or nonVitamin K oral anticoagulants. Primary outcome was the composite of stroke, transient ischemic attack, symptomatic systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding within 90 days from the inclusion. Treated-patients were propensity matched to untreated-patients in a 1:1 ratio after stratification by baseline clinical features. Results: A total of 2159 patients were included, 564 (26%) patients received acute reperfusion therapies. After the index event, 505 (90%) patients treated with acute reperfusion therapies and 1287 of 1595 (81%) patients untreated started oral anticoagulation. Timing of starting oral anticoagulant was similar in reperfusion-treated and untreated patients (median 7.5 versus 7.0 days, respectively). At 90 days, the primary study outcome occurred in 37 (7%) patients treated with reperfusion and in 146 (9%) untreated patients (odds ratio, 0.74 [95% CI, 0.50-1.07]). After propensity score matching, risk of primary outcome was comparable between the 2 groups (odds ratio, 1.06 [95% CI, 0.53-2.02]). Conclusions: Acute reperfusion treatment did not influence the risk of early recurrence and major bleeding in patients with atrial fibrillation-related acute ischemic stroke, who started on oral anticoagulant. © 2020 The Authors.en
dc.language.isoenen
dc.sourceStrokeen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85088847987&doi=10.1161%2fSTROKEAHA.120.030143&partnerID=40&md5=06275218a0b7754e113e0867aa96610a
dc.subjectalteplaseen
dc.subjectanticoagulant agenten
dc.subjectantivitamin Ken
dc.subjectenoxaparinen
dc.subjectlow molecular weight heparinen
dc.subjectanticoagulant agenten
dc.subjectageden
dc.subjectanticoagulant therapyen
dc.subjectArticleen
dc.subjectatrial fibrillationen
dc.subjectbleedingen
dc.subjectbrain ischemiaen
dc.subjectclinical outcomeen
dc.subjectcontrolled studyen
dc.subjectfemaleen
dc.subjectfibrinolytic therapyen
dc.subjecthumanen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmechanical thrombectomyen
dc.subjectpriority journalen
dc.subjectrecurrent diseaseen
dc.subjectsecondary preventionen
dc.subjectadverse eventen
dc.subjectatrial fibrillationen
dc.subjectbleedingen
dc.subjectblood clottingen
dc.subjectbrain ischemiaen
dc.subjectcerebrovascular accidenten
dc.subjectdrug effecten
dc.subjectfibrinolytic therapyen
dc.subjectmiddle ageden
dc.subjectphysiologyen
dc.subjectproceduresen
dc.subjectprospective studyen
dc.subjectreperfusionen
dc.subjectthrombectomyen
dc.subjecttreatment outcomeen
dc.subjectvery elderlyen
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAnticoagulantsen
dc.subjectAtrial Fibrillationen
dc.subjectBlood Coagulationen
dc.subjectBrain Ischemiaen
dc.subjectFemaleen
dc.subjectHemorrhageen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectProspective Studiesen
dc.subjectReperfusionen
dc.subjectStrokeen
dc.subjectThrombectomyen
dc.subjectThrombolytic Therapyen
dc.subjectTreatment Outcomeen
dc.subjectLippincott Williams and Wilkinsen
dc.titleSafety of Anticoagulation in Patients Treated with Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillationen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής